

Contact: Stacey May

(703) 248-4740
mays@aaps.org**AAPS Announces Eight Fellowships, One of the Highest Organizational Honors**
Fellows' Impactful Research Ranges From Therapies for Chronic Pain to Novel Drug Delivery Systems

San Diego (October 10, 2017) – The [American Association of Pharmaceutical Scientists](http://www.aaps.org) (AAPS) is pleased to announce the elevation of eight recipients to Fellow, one of the highest honors given to members of the association. Each year, AAPS elevates a few members to Fellow in recognition of their professional excellence in fields relevant to AAPS's mission: to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health.

Each Fellow has demonstrated a sustained level of superior and distinguished professional achievement and contributions in fields related to this mission. Fellows are nominated by supporters, selected by a committee of their peers, and elevated by AAPS' Executive Council.

David J. Brayden, Ph.D.

Professor David Brayden of University College Dublin, Ireland, has spent over 25 years in drug delivery research. His research focuses on how to deliver poorly permeable macromolecules across the intestinal epithelium in order to guide formulation of oral dosage forms. As author or co-author, he has published over 200 peer-reviewed articles of which 10 have been cited over 100 times. Currently, he is a co-lead Principle Investigator of Science Foundation Ireland's Centre for Medical Devices (CURAM).

Marianna Foldvari, Ph.D., Pharm.D.

Dr. Marianna Foldvari is a Professor of Pharmaceutical Sciences at the University of Waterloo's School of Pharmacy. She started her academic career at the University of Saskatchewan and held the prestigious Tier 1 Canada Research Chair in Bionanotechnology and Nanomedicine. Dr. Foldvari's research focuses on non-invasive, needle-free delivery systems and administration technologies. Dr. Foldvari's contributions to the drug delivery field in the past 28 years include basic and applied research accomplishments and commercialization of delivery technologies.

Filippos Kesisoglou, M.S., Ph.D.

Dr. Filippos Kesisoglou is a research scientist at Merck Research Laboratories. His research spans the fields of formulation development, biopharmaceutics and modeling and simulation. His publications have both advanced core biopharmaceutics knowledge as well as led to increased adoption of mechanistic oral absorption modeling and IVIVCs for formulation decisions. During his work at Merck, he has championed the integration of formulation, clinical and regulatory considerations to enable drug product development, focusing on drug product quality for the patient.

Donald E. Mager, Pharm.D., Ph.D.

Dr. Mager is a Professor of Pharmaceutical Sciences at the University at Buffalo, SUNY. He has mentored 30 graduate students, 11 post-doctoral fellows, 2 visiting scientists, and 4 undergraduate students. His research has made major contributions to structure-activity relationships in PK/PD, creating new theoretical concepts and applications related to target-mediated drug disposition, assessing properties of antibody-based therapeutics, developing cancer chemotherapy models, and evolving increasingly complex systems pharmacology models. His work is an example of the creative incorporation of mechanistically inspired computational modeling to provide a more robust framework for understanding drug action.

S. Narasimha Murthy, Ph.D.

Dr. Murthy's main research goal is to develop noninvasive technologies for the treatment of chronic disorders such as anemia, chronic pain and fungal infections. He has published over one hundred research papers and has delivered over 50 invited talks at various scientific conferences. His research programs are funded by NIH, USFDA and pharmaceutical companies. He is serving on the Editorial Advisory Board of several scientific journals. Dr. Murthy has founded a non-profit research organization, Institute for Drug Delivery and Biomedical Research in Bangalore India to foster research to address the unmet medical needs.

Mark Prausnitz, Ph.D.

Dr. Prausnitz has carried out research on targeted drug delivery to the skin, eye and other tissues. He founded the fields of skin electroporation and drug delivery using microneedle technology. Based on work in his lab, he co-founded four companies including Clearside Biomedical, which uses hollow microneedles to target drug delivery in the eye (currently being studied in two phase 3 clinical trials) and Micron Biomedical, which uses dissolvable microneedle patches to simply and painlessly administer drugs and vaccines without the need for hypodermic injection (which was studied in a successful phase 1 clinical trial of influenza vaccination).

Aliasger Karimjee Salem, Ph.D.

Dr. Salem is a full professor and an endowed chair of pharmaceutical sciences. His research program is currently focused on developing new therapeutic strategies for generating sustained stronger immune responses against tumors as well as developing new gene delivery based approaches to regrow bone and cartilage. Aliasger Salem is the associate editor for The AAPS Journal and has served as a theme editor and editorial board member for the International Journal of Pharmaceutics. Aliasger Salem is a member of a number of grant review study sections including panels for the ACS, NIH, NSF, and the DOD. Prof. Salem enjoys mentoring graduate students, research scientists and postdocs and teaching in the PharmD and graduate programs, and has received numerous awards for teaching.

Satish Singh, Ph.D.

Dr. Singh, in his industrial career, has worked on development programs ranging from small molecules to biotherapeutics, solids, suspensions, and parenterals. He has conducted research in areas such as freezing of biologics, computational tools for developability and structural origins of immunogenicity, and subvisible particles. For the latter, Satish has been involved in the evolution of regulations around control of this important quality attribute for biologics. He has been a significant contributor to AAPS meetings since 2006, as speaker, moderator and organizer of events of topical importance. He has more than 70 journal publications, and enjoys speaking, especially at universities to graduate students.

For more information about AAPS Fellows, visit [here](#).

#

About AAPS: The [American Association of Pharmaceutical Scientists](#) (AAPS) is a professional, scientific organization of approximately 9,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health. Visit www.aaps.org today and follow us on Twitter and Facebook, hashtag #AAPS.